Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients.

Tranulis C, Goff D, Henderson DC, Freudenreich O.

Psychiatr Serv. 2011 Aug;62(8):888-92. doi: 10.1176/appi.ps.62.8.888.

PMID:
21807827
2.

Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.

Uhlmann C, Kaehler J, Harris MS, Unser J, Arolt V, Lencer R.

J Psychiatr Pract. 2014 Sep;20(5):405-10. doi: 10.1097/01.pra.0000454787.75106.ae.

PMID:
25226204
3.

Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.

Moritz S, Hünsche A, Lincoln TM.

Eur Neuropsychopharmacol. 2014 Nov;24(11):1745-52. doi: 10.1016/j.euroneuro.2014.09.008. Epub 2014 Sep 16.

PMID:
25444234
4.

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C.

Arch Gen Psychiatry. 2005 Jul;62(7):717-24.

PMID:
15997012
5.

Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis.

Moritz S, Favrod J, Andreou C, Morrison AP, Bohn F, Veckenstedt R, Tonn P, Karow A.

Schizophr Bull. 2013 Jul;39(4):917-22. doi: 10.1093/schbul/sbs005. Epub 2012 Feb 15.

6.

Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.

Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M.

Schizophr Res. 2011 Aug;130(1-3):176-81. doi: 10.1016/j.schres.2011.04.030. Epub 2011 Jun 1. Erratum in: Schizophr Res.2013 May;146(1-3):379.

PMID:
21636254
7.

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60. doi: 10.1016/j.pnpbp.2007.12.002. Epub 2007 Dec 14.

PMID:
18226436
8.

Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.

Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, Biedermann F, Edlinger M, Kemmler G, Rettenbacher MA, Widschwendter CG, Zernig G, Fleischhacker WW, Hofer A.

Int J Neuropsychopharmacol. 2014 Dec 7;18(5). pii: pyu091. doi: 10.1093/ijnp/pyu091.

9.

How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R.

Psychiatry Res. 2011 May 15;187(1-2):55-61. doi: 10.1016/j.psychres.2010.10.012. Epub 2010 Nov 12.

PMID:
21074860
10.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
11.

Treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O.

J Clin Psychiatry. 2011 Apr;72(4):e13. doi: 10.4088/JCP.9096tx6cc.

12.
13.

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.

Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM.

BMC Psychiatry. 2009 Jul 29;9:46. doi: 10.1186/1471-244X-9-46.

14.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133
15.

Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD.

J Clin Psychiatry. 2013 Dec;74(12):1249-55. doi: 10.4088/JCP.12m08331.

16.

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR.

J Clin Psychiatry. 2006 Jul;67(7):1114-23.

PMID:
16889456
17.

Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.

Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R.

Schizophr Res. 2011 Oct;132(1):42-9. doi: 10.1016/j.schres.2011.07.019. Epub 2011 Aug 5.

PMID:
21820875
18.

Qualitative inquiry into motivators for maintaining medication adherence among Taiwanese with schizophrenia.

Chang YT, Tao SG, Lu CL.

Int J Ment Health Nurs. 2013 Jun;22(3):272-8. doi: 10.1111/j.1447-0349.2012.00864.x. Epub 2012 Aug 6.

PMID:
22882876
19.

Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.

Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC.

Schizophr Bull. 2011 Jul;37(4):727-36. doi: 10.1093/schbul/sbp121. Epub 2009 Nov 21.

20.

The influence of perceived social support on medication adherence in first-episode psychosis.

Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A.

Can J Psychiatry. 2013 Jan;58(1):59-65.

PMID:
23327758
Items per page

Supplemental Content

Write to the Help Desk